Roswell Park

Running trials

• Recruiting

  A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

  NCT06326411· Phase 1· Source

• Active, not recruiting

  Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

  NCT05665062· Phase 1· Source

• Active, not recruiting

  A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

  NCT05506943· Phase 2/3· Source

• Recruiting

  A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

  NCT04486352· Phase 1/2· Source

• Active, not recruiting

  A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

  NCT04215146· Phase 2· Source

• Active, not recruiting

  Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

  NCT04056247· Source

• Active, not recruiting

  Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

  NCT02477878· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Melanoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

  NCT07030907· Phase 1· Source

• Completed

  FT576 in Subjects With Multiple Myeloma

  NCT05182073· Phase 1· Source

• Completed

  CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

  NCT04681131· Phase 2· Source

• Completed

  Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

  NCT04374877· Phase 1· Source

• Completed

  Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

  NCT03258931· Phase 3· Source

• Completed

  CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

  NCT03504488· Phase 1/2· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· Source